Engflag

Mexitil

Quick links to important sections

Mexitil

Mexitil_SK

Method of action: Antiarrhythmic

Treatment option: Arrhythmia, Ventricular Arrhythmia, Ventricular Tachycardia, Tachycardia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mexitil

Property Description
Active ingredient Mexiletine hydrochloride
Form Oral capsule, Intravenous solution
Pharmacological class Class IB Antiarrhythmic Agent
Common use Stabilizing ventricular rhythm
Origin Synthetic

What Type of Medicine is Mexitil (Mexiletine)?

Mexitil is the former brand name for the synthetic prescription medicine containing the active substance Mexiletine hydrochloride. It is recognized as an antiarrhythmic agent and is specifically categorized as a Class IB antiarrhythmic drug according to the Vaughan-Williams classification. This classification is clinically significant because it targets a very specific phase of the heart's electrical cycle, differentiating it from other antiarrhythmic classes. Mexiletine is typically prescribed to adult patients facing potentially serious ventricular rhythm disturbances, a key focus that distinguishes its use.

Composition, Origin, and Available Forms

The therapeutic action of this medicine is derived exclusively from the Mexiletine hydrochloride compound, confirming it as a single-ingredient synthetic product. For patient management, the drug is primarily supplied for oral administration in the form of a capsule, offering a non-invasive method for long-term use. This oral capsule format is a crucial differentiating factor, making it suitable for out-of-hospital control of chronic conditions, unlike many other antiarrhythmic agents that require injection. While the capsule is the standard, an intravenous solution (IV) is also available for controlled, acute use in hospital settings.

General Purpose and Mechanism Principle

The overarching general purpose of Mexiletine is to promote a stable and functional rhythm, particularly in the lower chambers of the heart, when they exhibit rapid or erratic electrical activity. It accomplishes this goal by acting as a sodium channel blocker at the cellular level. This fundamental mechanism principle is clinically recognized for its ability to stabilize the cardiac tissue, preventing the uncontrolled generation of electrical impulses. By electrically stabilizing the cardiac tissue and dampening this abnormal excitability, Mexiletine helps reduce the occurrence and severity of dangerous rapid beats, supporting a more consistent and reliable heart rhythm.

What side effects are possible with Mexitil?

Possible Side Effects and Safety Information

Official regulatory documents classify the safety profile of Mexitil based on system-organ class, frequency, and specific warnings regarding clinically significant adverse reactions.

Documented Adverse Reactions

Side effects are often dose-related and classified by government authorities. The most frequently reported effects (Common) involve the Gastrointestinal and Nervous Systems, including nausea, vomiting, heartburn, dizziness, lightheadedness, and tremor.

Less common, yet documented, effects may include blurred vision, confusion, headache, numbness or tingling, skin rash, slurred speech, and fast or irregular heartbeat. Rare but serious reactions include seizures, severe allergic reactions, and severe liver injury.

System-Organ Class
Cardiac Disorders Proarrhythmic effects (new or worsened arrhythmias), conduction disturbances, or exacerbation of pre-existing heart failure.
Gastrointestinal Disorders Nausea, heartburn, vomiting, dyspepsia; esophageal ulceration if capsules lodge in the esophagus.
Nervous System Disorders Dizziness, tremor, ataxia, paresthesia, seizures/convulsions.
Blood and Lymphatic Rare reports of hematologic changes, including agranulocytosis and leukopenia.
Immune System Severe Cutaneous Adverse Drug Reactions (SCARs), such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome.

Safety Restrictions and Monitoring

Official documents define specific limitations and conditions requiring heightened caution or monitoring:

  • Contraindications include cardiogenic shock, pre-existing second- or third-degree AV block (without a pacemaker), and known hypersensitivity to mexiletine or local anesthetics (e.g., lidocaine).
  • Use Limitations apply to patients with severe hepatic impairment or severe renal impairment, requiring careful individual dose adjustment due to altered elimination rates.
  • Cardiovascular Risk: The drug is generally not recommended for lesser arrhythmias due to its proarrhythmic potential. Caution is mandated for patients with a history of seizures, heart failure, or severe myocardial infarction.
  • Drug Interactions: Concurrent use with certain medications that affect liver enzymes (CYP1A2 or CYP2D6 inhibitors or inducers) or co-administration with other antiarrhythmics or drugs known to prolong the QT interval may alter Mexitil's plasma concentration or increase the risk of adverse cardiac events. Electrolyte imbalances must be corrected prior to and monitored during therapy.

This regulatory framework establishes the drug's risk profile, highlighting critical cardiac and systemic risks and defining the clinical boundaries for its use.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose with Mexitil (mexiletine hydrochloride) constitutes a documented emergency requiring immediate professional action. Regulatory authorities explicitly mandate that individuals must contact emergency services or report immediately to the nearest accident and emergency center upon suspicion of an overdose.

Documented Manifestations and Severe Outcomes

Official prescribing information describes overdose as a profile of severe manifestations across the central nervous system (CNS) and cardiovascular system. CNS effects may include confusion, paresthesia, seizures or convulsions, and progression to coma. Gastrointestinal effects such as nausea are also listed.

The most life-threatening outcomes are cardiac events, including profound hypotension, sinus bradycardia, and various forms of severe cardiac conduction delays, such as AV heart block and bundle branch block. Overdose can rapidly escalate to ventricular tachyarrhythmia, ventricular fibrillation, asystole, and cardiovascular collapse, leading to documented fatal outcomes.

Required Management and Considerations

No specific antidote is known for Mexitil overdose. Management is solely symptomatic and supportive, often requiring hospitalization and continuous ECG monitoring to manage the cardiac risks. Interventions may involve procedures such as gastric lavage or activated charcoal for drug removal, and specific medications (e.g., sodium bicarbonate) for managing severe cardiac conduction abnormalities. Regulatory documents also note that patients with severe liver disease may have an increased risk of toxicity due to impaired drug clearance.

Therapeutic Uses of Mexitil

The primary role of this medication is to provide therapeutic support across two distinct domains where symptoms are driven by increased neurological or muscular activity and heightened physiological processes. It is applied across domains where additional symptomatic support is needed.

Stabilization of Serious Ventricular Rhythm Disturbances

This medicine is commonly used to help with the management of documented, serious or severe ventricular arrhythmias, such as sustained ventricular tachycardia. It is used in conditions characterized by periods of heightened symptoms related to aberrant cardiac electrical activity. The benefit achieved is to address symptoms related to the heart's erratic activity, which may assist with managing the occurrence of challenging ventricular manifestations and helps maintain a sense of stability. It is considered relevant applied in clinical settings that involve acute or unstable symptom patterns.

Symptomatic Relief for Muscle Stiffness (Myotonia)

A key secondary use is to address symptom clusters that may become intense or disruptive, specifically myotonia associated with inherited conditions like Non-Dystrophic Myotonia. The medication is relevant for managing symptoms that interfere with daily comfort. For patients with these disorders, it is relevant for easing the overall symptom load related to delayed muscle relaxation. This symptomatic relief assists with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.

“This medicine is commonly used to help with the management of serious or severe ventricular arrhythmias.”

Quick Fact: Supportive Care: Muscle Stiffness The medication may assist with the physical strain associated with myotonia, supporting the patient's functional independence during symptomatic periods.

The two main categories of conditions for which this medicine is commonly used are serious ventricular arrhythmias and inherited myotonic disorders, including Non-Dystrophic Myotonia.

Eligibility and Restrictions for Use

Mexiletine (Mexitil) eligibility is determined by specific cardiac conditions, organ function, and age, as defined in official regulatory labeling. Use is generally established for adults for the treatment of documented life-threatening ventricular arrhythmias or, in certain regions, symptomatic non-dystrophic myotonia. Safety and efficacy in the pediatric population (children and adolescents) have not been established.

Contraindicated Populations (Must Not Use)

The medicine is contraindicated and must not be used in the following circumstances:

  • Patients experiencing Cardiogenic Shock.
  • Individuals with preexisting Second- or Third-Degree Atrioventricular (AV) Block when a functioning cardiac pacemaker is not present.
  • Patients with known Hypersensitivity to mexiletine, its components, or to local anesthetics of the amide type (e.g., lidocaine).

Restricted and Conditional Use

Special Population Eligibility Status as Labeled
Severe Hepatic Impairment Not recommended due to limited clinical experience.
Severe Renal Impairment Not recommended due to limited clinical experience.
Pregnancy Status Assigned Pregnancy Category C; use only if the potential benefit justifies the potential risk.
Lactation Status Drug is excreted into human milk; manufacturer recommends discontinuing nursing or the drug.
Conduction Defects Patients with First-Degree AV Block or Sinus Node Dysfunction require careful monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Mexiletine (Mexitil) has officially documented interaction patterns primarily involving hepatic metabolism and cardiac electrophysiology, as classified in regulatory documents.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Classification Official Interaction Statement
Contraindicated Combinations Co-administration is prohibited with specific CYP1A2 substrates, such as Alosetron and Tizanidine, because Mexiletine is a moderate CYP1A2 inhibitor that increases their plasma concentration. Combinations with drugs like Pimozide and Dofetilide are also contraindicated due to the risk of additive cardiac effects and QTc prolongation.
Metabolic Interactions (PK) Mexiletine is a primary substrate of the CYP2D6 enzyme. Co-administration with CYP2D6 inhibitors (e.g., Quinidine, Fluoxetine) may increase Mexiletine plasma concentration by reducing its clearance. Conversely, CYP inducers (e.g., Rifampin, Phenytoin) may decrease Mexiletine exposure by enhancing its metabolism.
Physiological Interactions Substances that markedly alter urinary pH to alkaline (e.g., urinary alkalinizers) decrease Mexiletine excretion, resulting in increased serum concentration. Cigarette smoking is documented to enhance the rate of elimination, reducing exposure.

Interaction-Related Restrictions and Considerations

The interaction profile includes the constraint that the drug’s elimination half-life is prolonged in hepatic impairment or liver disease, which may lead to increased exposure and heightened interaction risk. Caution is required with other Antiarrhythmic Agents due to the officially documented risk of additive arrhythmogenic activities.

Mechanism of Action

Mexiletine's mechanism involves the targeting and inhibition of voltage-gated sodium channels ( Nav), primarily suppressing the fast sodium current ( I Na) that governs the electrical upstroke of the cardiac action potential. This action reduces the excitability and maximum rate of depolarization in heart muscle cells. The drug exhibits state-dependent and use-dependent binding, preferentially interacting with Na^+ channels in the inactivated state, which are abundant during rapid electrical activity. This selectivity allows the mechanism to result in the suppression of ectopic automaticity—uncontrolled, spontaneous electrical firing—while exhibiting minimal effect on normally conducting tissue. By dampening this hyperactivity, the mechanism facilitates the electrical stabilization of the ventricular rhythm. A defining cellular effect is the shortening of the action potential duration ( APD) in certain cardiac fibers. This modification of the electrical recovery time, coupled with the suppression of abnormal impulse generation, modifies the electrical dynamics within the cardiac conduction pathways.

Dosage and Administration Information

Official Administration Guidelines

Mexiletine hydrochloride is an antiarrhythmic medicine used according to strict protocols. The medication is available primarily as an oral capsule for maintenance therapy and historically as an intravenous (IV) solution for acute management, typically initiated under continuous monitoring.

Dosing and Administration Structure

The total daily dose is typically administered in two or three divided doses to ensure consistent drug concentrations in the body. The typical maintenance range is 600 mg to 900 mg per day, with the dosage adjusted in controlled increments, generally 50 mg or 100 mg, after a minimum of 2 to 3 days. The maximum recommended daily dose for ventricular arrhythmias is 1200 mg.

Procedural Requirements

Instruction Category Official Labeled Requirement
Intake Condition Capsules must be taken with food, milk, or an antacid (or immediately after a meal) to minimize gastrointestinal discomfort.
Handling Constraint Capsules must be swallowed whole with an ample amount of liquid; they must not be crushed, opened, or chewed.
Dose Adjustment Dose reduction is typically necessary for patients with severe hepatic (liver) impairment; no mandatory adjustment is required for standard renal impairment.
Switching Therapy Oral administration is only initiated after the cessation of any prior continuous intravenous lidocaine infusion.

These instructions define the standardized approach to utilizing Mexiletine, structuring the regimen based on the constraints of divided daily dosing, specific intake requirements, and necessary adjustments for impaired organ function.

Recent Clinical Evidence

Mexiletine (Mexitil) is an oral antiarrhythmic drug primarily studied for the management of documented ventricular arrhythmias considered life-threatening. Its use has also been investigated in other conditions, particularly certain inherited cardiac channelopathies and neuromuscular disorders.

Core Antiarrhythmic Use

Clinical trials have shown that mexiletine can lead to a significant reduction in the frequency of premature ventricular contractions (PVCs) and episodes of non-sustained ventricular tachycardia compared to placebo. It is classified as a Class IB antiarrhythmic agent. Key research findings include:

  • Long QT Syndrome Type 3 (LQT3): Mexiletine is a therapeutic option in LQT3, where studies suggest it can shorten the corrected QT interval (QTc), which may help reduce the risk of arrhythmias in this specific genotype.
  • Refractory Arrhythmias: Evidence indicates that mexiletine, often used as an adjunct to other antiarrhythmic drugs or in patients who have not responded to initial therapy, may help suppress recurrent ventricular arrhythmias, including in those with structural heart disease and implantable cardioverter defibrillators (ICDs).

Limitations and Safety Context

Older, large-scale trials, such as the Cardiac Arrhythmia Suppression Trial (CAST), have highlighted that the use of Class I antiarrhythmic drugs for asymptomatic, non-life-threatening ventricular arrhythmias following myocardial infarction may be associated with an increased risk of mortality. This finding strongly influences the current clinical guidance, reserving mexiletine for documented life-threatening arrhythmias. The impact of mexiletine on long-term survival in all patient populations remains uncertain, and its safety profile is a central consideration when evaluating its potential use.

Frequently Asked Questions (FAQ)

Common questions about Mexitil (FAQ)

Q: What should I do if I miss a dose of Mexiletine?

If a dose of Mexiletine is missed, official regulatory documents advise taking the dose as soon as it is remembered. However, if it is almost time for your next scheduled dose, the label recommends skipping the missed dose and returning to the regular dosing schedule. Official guidelines caution against taking two doses at once to attempt to make up for a missed dose.

Q: How long does it take for Mexiletine to start working?

Official product information, based on studies of how the drug behaves in the body, indicates that the active substance reaches its highest level in the blood (peak plasma concentration) approximately two to three hours after the oral capsule is taken. This indicates that the medicine is quickly absorbed into the bloodstream.

Q: Is it safe to drive or operate machinery while taking Mexiletine?

Official product labeling notes that Mexiletine can cause nervous system side effects such as dizziness, lightheadedness, and difficulty with coordination (ataxia). Because these effects may impact focus, patients should be aware that caution may be required for activities like driving or operating machinery, which demand full alertness.

Q: When did the FDA first approve Mexiletine?

The FDA originally approved the brand product, Mexitil, in December 1985. The generic version, Mexiletine Hydrochloride Capsules, was subsequently approved by the FDA in April 1998.

How should Mexitil be stored and disposed of?

How to Store and Dispose of Mexiletine Capsules

Official regulatory guidelines strictly govern the storage and disposal of mexiletine hydrochloride capsules to maintain quality and safety.

Scope Element Required Regulatory Statement
Storage Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Environmental Protection Keep the medicine away from excess heat, moisture, and light. It must also be kept from freezing.
Container Requirements Dispense and store in a tight, light-resistant container with a child-resistant closure.
Child Safety The medication must be stored out of the reach of children.
Disposal Instructions Unused or expired medication must not be kept and should be disposed of safely. Follow official FDA guidelines or use a community drug take-back program for safe discarding.

These statements define how the product must be stored, handled, and discarded, ensuring its stability until the expiration date and preventing unintended exposure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagEgypt

flagGreece

flagIndia

flagJapan

flagTaiwan

flagUSA

Equivalent of Mexitil found in:

A-Z Index: